Most Effective GLP-1 for Weight Loss (2026)

See if you qualify — 5-minute assessment →
5-minute questionnaire · reviewed by a licensed clinician · The Nouri Promise: full refund in your first 30 days (3- and 6-month plans) · cancel anytime

At a glance

	Semaglutide (Wegovy®/Ozempic®)	Tirzepatide (Zepbound®/Mounjaro®)
Mechanism	GLP-1 receptor agonist	Dual GIP + GLP-1 receptor agonist
Average weight loss — pivotal trial	~14.9% (STEP-1, 68 wks)	~20.9% (SURMOUNT-1, 72 wks, 15 mg)
Head-to-head (SURMOUNT-5)	~13.7%	~20.2%
Cardiovascular-outcomes data	SELECT (20% ↓ MACE, NEJM 2023)	SURPASS-CVOT — ongoing
Weight-management FDA approval	Wegovy® (2021)	Zepbound® (2023)
Timeline to near-maximal effect	~68 weeks	~72 weeks

All figures are from clinical trials of the FDA-approved branded medications — population averages, not individual outcomes. Compounded semaglutide and tirzepatide were not studied in these trials and are not FDA-approved.

How these medications work — and why the numbers differ

Both semaglutide and tirzepatide belong to the GLP-1 class, but they act through different receptor combinations, and that difference is the most likely explanation for the gap in average weight-loss outcomes seen in trials of the branded drugs.

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. GLP-1 is a gut hormone released after eating; it slows gastric emptying, amplifies satiety signals, and reduces appetite by acting on receptors in the hypothalamus and brainstem. The FDA-approved Wegovy® (semaglutide 2.4 mg weekly) is the weight-management formulation; Ozempic® (semaglutide at lower doses) is approved for type 2 diabetes.

Tirzepatide activates two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is a second incretin hormone that appears to complement and amplify GLP-1's appetite-suppressing and metabolic effects when both receptors are engaged simultaneously. The FDA-approved Zepbound® (tirzepatide for weight management) and Mounjaro® (tirzepatide for type 2 diabetes) use this dual mechanism. The additional GIP receptor activity is the most widely cited mechanistic explanation for why tirzepatide produced larger average weight-loss outcomes than semaglutide in head-to-head trials of the branded drugs.

Both medications carry a boxed warning for thyroid C-cell tumors and share common GI side effects — nausea, vomiting, diarrhea, and constipation — most pronounced during dose titration. For a detailed side-effect comparison, see our guide to which GLP-1 has the fewest side effects.

What the trials show

The following numbers are from randomized controlled trials of the FDA-approved branded medications. Compounded semaglutide and compounded tirzepatide were not enrolled in these trials and these results do not apply to compounded products.

STEP-1 — semaglutide (Wegovy®), NEJM 2021

The pivotal STEP-1 trial (Wilding et al.) enrolled 1,961 adults with obesity or overweight plus at least one weight-related comorbidity and no type 2 diabetes. Participants received weekly semaglutide 2.4 mg or placebo alongside lifestyle counseling over 68 weeks. Average weight loss with semaglutide was ~14.9% of body weight versus 2.4% with placebo. Approximately 86% of those on semaglutide lost at least 5% of body weight; about 69% lost 10% or more.

SURMOUNT-1 — tirzepatide (Zepbound®), NEJM 2022

The SURMOUNT-1 trial (Jastreboff et al.) enrolled 2,539 adults with obesity or overweight plus at least one comorbidity, excluding type 2 diabetes. Over 72 weeks, the highest weekly dose (15 mg tirzepatide) produced average weight loss of ~20.9% of body weight; the 10 mg dose averaged ~19.5%, and the 5 mg dose ~15.0%. About 91% on the 15 mg dose lost at least 5% of body weight, and approximately 57% lost 20% or more. Placebo-group average weight loss was ~3.1%.

SURMOUNT-5 — head-to-head, NEJM 2025

The most direct evidence is the SURMOUNT-5 trial, which compared tirzepatide directly against semaglutide 2.4 mg in adults with obesity or overweight without type 2 diabetes over 72 weeks. Tirzepatide produced average weight loss of ~20.2% versus ~13.7% for semaglutide — a difference of approximately 6.5 percentage points. This is the highest-quality direct comparative evidence available for the two molecules.

SELECT — cardiovascular outcomes with semaglutide, NEJM 2023

Average weight loss is not the only clinically relevant outcome. The SELECT trial (Lincoff et al.) enrolled 17,604 adults with established cardiovascular disease and overweight or obesity, without type 2 diabetes. Semaglutide 2.4 mg weekly reduced the risk of major adverse cardiovascular events (MACE — heart attack, stroke, or cardiovascular death) by 20% relative to placebo. This makes semaglutide the only GLP-1 medication in this weight-management setting with published CV-outcomes data. Tirzepatide's cardiovascular-outcomes trial (SURPASS-CVOT) is ongoing; results are not yet published. For patients with a history of heart disease, this distinction may be clinically significant — a question for a licensed prescriber.

Reading the averages: what the numbers do and don't tell you

These are population averages from large controlled trials conducted with specific branded, FDA-approved medications under specific conditions. Several points are important before applying them to any individual situation:

• Wide individual variation. In SURMOUNT-1, some participants on 15 mg tirzepatide lost more than 35% of body weight; others lost less than 5%. The reported average (20.9%) is the midpoint of a broad distribution. The same pattern holds for semaglutide in STEP-1. Averages describe populations, not individuals.
• Dose dependence. The headline numbers reflect the highest approved doses titrated to maximum. Patients who cannot tolerate higher doses — a common occurrence — will generally see outcomes closer to lower-dose averages.
• Lifestyle context. Both pivotal trials combined medication with structured lifestyle counseling — reduced-calorie diet and increased physical activity. The medication effect is real and substantial, but it operates alongside behavioral change, not instead of it.
• Compounded medications were not studied in these trials. The STEP, SURMOUNT, and SELECT trials enrolled participants receiving FDA-approved branded products. Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not therapeutically equivalent to the branded drugs studied. The trial results described here cannot be attributed to compounded products.
• Responder rates matter. About 57% of participants on the highest tirzepatide dose in SURMOUNT-1 lost 20% or more of body weight, versus about 34% on semaglutide 2.4 mg in STEP-1. These responder-rate differences can be clinically meaningful alongside the averages.

"Most effective" is personal: four factors that shape your outcome

The trials answer "which molecule produced greater average weight loss across a study population." They do not answer "which is most effective for me." Four factors heavily influence individual outcomes:

1. Tolerability

Nausea, vomiting, and GI symptoms are the most common reasons participants reduce dose or discontinue GLP-1 medications in trials. A person who tolerates semaglutide well and remains consistent at 2.4 mg may achieve better real-world results than someone who cannot reach or sustain the highest tirzepatide dose. The medication you can consistently take is, functionally, the effective one for you. For a full side-effect comparison, see which GLP-1 has the fewest side effects.

2. Your health profile

A prescriber weighs your complete picture: cardiovascular history (SELECT data for semaglutide is relevant for those with established CVD), other medications, kidney function, and contraindications including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2). These variables belong in a clinical conversation, not a self-service comparison table.

3. Cost and access

Brand-name Wegovy® and Zepbound® typically list at over $1,000 per month before insurance coverage or manufacturer savings programs, and prior authorization requirements are challenging for many patients (as of June 2026). For current pricing across brand-name and compounded options, see our guide to GLP-1 costs in 2026, along with the detailed tirzepatide cost guide and semaglutide cost guide. Our live GLP-1 telehealth pricing dataset tracks compounded and brand-name options updated for 2026. Compounded GLP-1 medications may also be eligible for FSA/HSA reimbursement under IRC §213(d) — see our guide to GLP-1 FSA/HSA eligibility for what the rules require and how to confirm with your plan administrator.

4. Consistency and support

GLP-1 medications require consistent, long-term use. Weight regain after discontinuation is well-documented: STEP-4, an extension trial, showed significant weight regain within approximately one year of stopping semaglutide, confirming that these medications manage obesity as an ongoing condition rather than a one-time course of treatment. Sustained effectiveness depends on staying on the medication and, increasingly, on pairing it with structured nutritional and behavioral support to build habits that hold over time.

How fast does a GLP-1 work for weight loss?

The timeline is measured in months, not days or weeks. Here is what the evidence shows:

• Weeks 1–4: Reduced appetite is often noticeable early, even at the low starting doses used during titration. Some people report decreased hunger and food preoccupation within the first few weeks.
• Months 1–3: Early weight loss begins as appetite consistently decreases. Doses are still being titrated upward in monthly increments, so the full appetite-suppressing effect has not yet been reached.
• Months 3–12: Weight loss accelerates toward the maximum maintenance dose. Most of the trial-average weight loss accumulates during this window.
• Months 12–18: Weight loss begins to plateau as participants approach near-maximal effect — the time points at which the STEP-1 (68 weeks) and SURMOUNT-1 (72 weeks) primary endpoints were measured.
• Long term: Continued treatment is required for weight maintenance. Discontinuation leads to substantial weight regain, as documented in the STEP-4 extension trial.

Any claim of rapid or dramatic short-term weight loss from GLP-1 therapy misrepresents what the evidence actually shows.

Related comparisons

• Tirzepatide vs Semaglutide: Full Comparison
• Which GLP-1 Has the Fewest Side Effects?
• Brand-Name vs Compounded GLP-1: What's the Difference?
• Ozempic vs Wegovy: Same Molecule, Different Doses
• Zepbound vs Ozempic: Cross-Molecule Comparison
• Compounded vs Brand-Name GLP-1: Cost Comparison

Where Nouri fits

If you and a licensed clinician determine that a GLP-1 is appropriate for you, Nouri offers compounded semaglutide and compounded tirzepatide as part of one complete program — clinician-guided treatment when prescribed, nutrition planning, a movement plan, and behavioral support, all at one price. Any dose, same price. Longer commitments reduce the monthly cost.

Compounded semaglutide: $120/month on the six-month plan ($720 billed every six months); $145/month on the three-month plan ($435 billed every three months); $175/month billed monthly. Compounded tirzepatide: $175/month on the six-month plan ($1,050 every six months); $199/month on the three-month plan ($597 every three months); $225/month billed monthly.

Medication is prepared by Jungle Jim's Pharmacy, a state-licensed 503A compounding pharmacy in Fairfield, OH, and VialsRX. Nouri is LegitScript-certified. Available in all 50 states.

Important: Compounded semaglutide and compounded tirzepatide contain the active ingredient(s) of the referenced branded medications but are not FDA-approved and are not the same as, or therapeutically equivalent to, Wegovy®, Ozempic®, Zepbound®, or Mounjaro®. The clinical-trial results described throughout this article are from studies of those FDA-approved branded products; they cannot be attributed to Nouri's compounded medications or to The Program.

The Nouri Promise: if you're not satisfied in your first 30 days, you get a full refund — available on 3-month and 6-month plans.

Start your 5-minute assessment →
5-minute questionnaire · reviewed by a licensed clinician · full refund in your first 30 days (3- and 6-month plans) · cancel anytime

Frequently asked questions

What is the most effective GLP-1 for weight loss?

By average weight loss in trials of FDA-approved medications, tirzepatide (Zepbound®/Mounjaro®) leads — about 20.2% vs 13.7% for semaglutide in the head-to-head SURMOUNT-5 trial (NEJM, 2025). These are population averages from trials of the branded drugs. The most effective option for any individual depends on tolerability, health profile, cost, and consistency — which is why it requires a clinician's assessment, not a self-service ranking.

What's the difference between Ozempic, Wegovy, Mounjaro, and Zepbound?

Ozempic® and Wegovy® both contain semaglutide — Ozempic® is FDA-approved for type 2 diabetes management, Wegovy® for chronic weight management at the higher 2.4 mg weekly dose. Mounjaro® and Zepbound® both contain tirzepatide — Mounjaro® for type 2 diabetes, Zepbound® for chronic weight management. For weight loss, the relevant branded products are Wegovy® (semaglutide) and Zepbound® (tirzepatide).

What is the strongest weight loss injection?

Among FDA-approved GLP-1 medications, tirzepatide (Zepbound®/Mounjaro®) has produced the greatest average weight loss in clinical trials — up to ~20.9% in SURMOUNT-1 and ~20.2% vs ~13.7% for semaglutide in SURMOUNT-5. Whether it is the strongest for any individual depends on tolerability and the ability to reach and sustain the highest dose. See our full tirzepatide vs semaglutide comparison for more detail.

How much weight can you lose on a GLP-1?

In trials of the FDA-approved medications, average weight loss was approximately 14.9% for semaglutide (STEP-1, 68 weeks) and up to ~20.9% for tirzepatide at the highest dose (SURMOUNT-1, 72 weeks). Individual results varied widely in both trials. These figures are from trials of the branded drugs; compounded semaglutide and tirzepatide were not studied in these trials, are not FDA-approved, and are not therapeutically equivalent to the branded products.

How fast do GLP-1s work for weight loss?

Appetite reduction is often noticeable within the first few weeks as dosing begins, but meaningful weight loss accumulates over months as the dose is titrated upward. The pivotal trials measured near-maximal effect at 68 to 72 weeks. Any promise of rapid transformation misrepresents what the evidence shows.

Does my health history affect which GLP-1 is most effective for me?

Yes. For patients with established cardiovascular disease, semaglutide has published CV-outcomes data — the SELECT trial showed a 20% reduction in major adverse cardiovascular events — while tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is still ongoing. For weight loss as the primary goal in the absence of cardiovascular history, tirzepatide has led in average outcomes in head-to-head trials. Your prescriber weighs your full health picture to determine what is clinically appropriate.

Sources & references

1. SURMOUNT-5 head-to-head (tirzepatide vs semaglutide), NEJM 2025 — Tier 1 (primary trial)
2. SURMOUNT-1 (tirzepatide), Jastreboff et al., NEJM 2022 — Tier 1 (primary trial)
3. STEP-1 (semaglutide), Wilding et al., NEJM 2021 — Tier 1 (primary trial)
4. SELECT (semaglutide cardiovascular outcomes), Lincoff et al., NEJM 2023 — Tier 1 (primary trial)
5. NIDDK: Prescription Medications to Treat Overweight and Obesity — Tier 1 (NIH/gov)
6. FDA: Human Drug Compounding — Tier 1 (FDA/gov)
7. FDA: Postmarket Drug Safety Information — GLP-1 receptor agonists — Tier 1 (FDA/gov)

Medically reviewed by Amber Patel, MD. Content prepared by the Nouri Editorial Team and reviewed by a licensed clinician before publication. Updated as clinical guidance and regulatory status change.

This article is general education, not medical advice — talk to a licensed clinician about what is right for you. Ozempic®, Wegovy®, and Rybelsus® (semaglutide) are registered trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® (tirzepatide) are registered trademarks of Eli Lilly and Company. Nouri is not affiliated with, endorsed by, or sponsored by these companies. Clinical-trial results described in this article are from studies of the FDA-approved branded medications; compounded semaglutide and compounded tirzepatide have not been studied in these trials, are not FDA-approved, and are not the same as — or therapeutically equivalent to — the brand-name products. GLP-1 medications carry a boxed warning for thyroid C-cell tumors (medullary thyroid carcinoma) and are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2); additional risks include pancreatitis and gallbladder disease, and these medications are not for use during pregnancy. Brand-name list prices cited are approximate as of June 2026 and change frequently; actual cost depends on insurance coverage and manufacturer programs. Nouri prices are as of June 2026; see joinnouri.com/becoming for current pricing.